Denali Therapeutics Inc. (DNLI) Tops Q2 EPS by 199c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of $1.30, $1.99 better than the analyst estimate of ($0.69). Revenue for the quarter came in at $294.12 million versus the consensus estimate of $39.51 million.

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Benchmark Reiterates Buy Rating on H World Group Ltd. (HTHT) Following Q2 Print
• Terra Innovatum Global N.V. (NKLR) Misses Q2 EPS by 12c